Summary

Gastrointestinal disease is a very common and frequently occurring disease, with a wide range of types and a total incidence of about 20% of the population. The cause of gastrointestinal disease is the imbalance between the protective mechanism and the injury mechanism of the human body. While traditional medicine kills harmful bacteria in the stomach, it also kills the beneficial bacteria necessary for the stomach. Although the symptoms are alleviated and inflammation is eliminated, the reduction of beneficial bacteria reduces the gastrointestinal immunity. Once the drug is stopped, it is easy to re-infect. There are many reasons for stomach problems, including genetics, environment, diet, drugs, bacterial infections, etc., as well as smoking and excessive alcohol consumption. This collection of entries aims to collect various items related to the topic of gastrointestinal diseases, such as clinical care, case cases, disease research, etc., to help people increase their knowledge and understanding of this common disease

Expand All
Entries
Topic Review
Anti-TNFs in Pediatric Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic immune-mediated condition that affects the gastrointestinal tract. The incidence of the disease in children is increasing. However, most clinical trials in this disease have been carried out in adults, and the results have been extrapolated with minimal changes to determine treatment in children. Pediatric IBD (pIBD) is characterized by various factors, including a more severe phenotype than adult diseas. Since IBD is a chronic autoimmune disease, patients diagnosed during childhood live longer with the illness and consequently need treatment for longer. Biological drugs and, more specifically, anti-TNF drugs such as infliximab and adalimumab have proven efficient for treatment of IBD in adults and in children. However, the use of biological drugs differs between children and adults with IBD. For instance, the time between diagnosis and initiation of biological treatment is shorter in children than in adults. In addition, not all the biological drugs approved for adult IBD are approved for children. 
  • 561
  • 17 Nov 2021
Topic Review
Intestinal Microbiota as a Contributor to Chronic Inflammation
The gut microbiota is a crucial factor in maintaining homeostasis. The presence of commensal microorganisms leads to the stimulation of the immune system and its maturation. In turn, dysbiosis with an impaired intestinal barrier leads to accelerated contact of microbiota with the host’s immune cells. Microbial structural parts, i.e., pathogen-associated molecular patterns (PAMPs), such as flagellin (FLG), peptidoglycan (PGN), lipoteichoic acid (LTA), and lipopolysaccharide (LPS), induce inflammation via activation of pattern recognition receptors. Microbial metabolites can also develop chronic low-grade inflammation, which is the cause of many metabolic diseases. 
  • 511
  • 28 Nov 2021
Topic Review
Enteric Glial Cells
 At first, enteric glial cells were considered to be just a structural support for neurons, but recent findings emphasized more on their functions, and they turned out to be equally as important as neural cells, due to their involvement in all aspects of neural functions for both the central and peripheral nervous system, including the ENS.They have been mostly underestimated, particularly regarding the modulation of their functions by nutraceuticals.
  • 636
  • 09 Nov 2021
Topic Review
Microbiome-Immune Interactions in Ulcerative Colitis
Inflammatory bowel disease (IBD) is a chronic autoimmune condition affecting the gastrointestinal (GI) tract. IBD includes Crohn’s disease (CD) and ulcerative colitis (UC), with UC characterized by inflammation of colonic mucosa and submucosa starting at the rectum and extending through the colon. The precise etiology of UC is unknown but is thought to involve a combination of environmental and genetic factors. Chief among these is the intestinal microbiome, which has been extensively studied both for its role in disease pathogenesis and possible treatment. In this review, we will discuss the microbial changes that have been described in UC, its interplay with host immune function, and evidence supporting its role as a potential therapeutic. We will also discuss parallels between UC, the microbiome and colitis-associated cancer (CAC).   
  • 618
  • 05 Nov 2021
Topic Review
Moderate Alcohol Intake in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is defined by hepatic steatosis in the presence of alcohol intake within safe limits, defined by guidelines of scientific associations (usually 20 g or 2 units/day in women, 30 g or 3 units in men). The diagnosis is usually followed by medical counseling of total abstinence, in order to prevent disease progression. Old evidence regarding a possible safe and eventually beneficial effect of alcohol intake in NAFLD have however been extensively challenged by data suggesting a detrimental effects of alcohol on other organs and tissues, namely the cardiovascular system and cancer risk. Current guidelines support alcohol abstinence for individuals with NAFLD. 
  • 523
  • 04 Nov 2021
Topic Review
Sinistral Portal Hypertension after Pancreaticoduodenectomy
To achieve curative resection for pancreatic cancer during pancreaticoduodenectomy (PD), extensive portal vein (PV) resection, including porto-mesenterico-splenic confluence (PMSC), may sometimes be necessary if the tumor is close to the portal venous system. Recently, this extended resection has been widely accepted in high-volume centers for pancreatic resection due to its favorable outcomes compared with non-operative treatment. However, in patients with long-term survival, sinistral portal hypertension (SPH) occurs as a late-onset postoperative complication. These patients present gastrointestinal varices due to congested venous flow from the spleen, which may cause critical variceal bleeding.
  • 469
  • 02 Nov 2021
Topic Review
The Association of Gut Microbiota in Gastrointestinal-Cancer Therapies
The gut microbiome of patients with gastrointestinal cancer undergoes specific changes during different therapies such as surgery, chemotherapy and radiation. Likewise, complications of these therapies are associated with specific changes in the microbiome. 
  • 660
  • 02 Nov 2021
Topic Review
Heat Shock Proteins in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a multifactorial human intestinal disease that arises from numerous, yet incompletely defined, factors. Two main forms, Crohn’s disease (CD) and ulcerative colitis (UC), lead to a chronic pathological form. Heat shock proteins (HSPs) are stress-responsive molecules involved in various pathophysiological processes.
  • 685
  • 01 Nov 2021
Topic Review
Lactoferrin
Lactoferrin (Lf) is an iron-binding milk glycoprotein that promotes the growth of selected probiotic strains. The effect of Lf on the growth and diversification of intestinal microbiota may have an impact on several issues, including (i) strengthening the permeability of the epithelial cell monolayer, (ii) favoring the microbial antagonism that discourages the colonization and proliferation of enteric pathogens, (iii) enhancing the growth and maturation of cell-monolayer components and gut nerve fibers, and (iv) providing signals to balance the anti- and pro-inflammatory responses resulting in gut homeostasis.
  • 997
  • 02 Nov 2021
Topic Review
Heat Shock Proteins in Colorectal Carcinoma
Cancer cells can reprogram their metabolic activities and undergo uncontrolled proliferation by utilizing the power of heat shock proteins (HSPs). HSPs are highly conserved chaperones that facilitate the folding of intracellular proteins under stress. Constitutively, HSPs are expressed at low levels, but their expression upregulates in response to a wide variety of insults, including anticancer drugs, allowing cancer cells to develop chemoresistance.
  • 486
  • 01 Nov 2021
  • Page
  • of
  • 39

Featured Entry Collections

>>